carboquone

Carboquone is an aziridinylbenzoquinone-based alkylating agent developed as a chemotherapeutic drug for the treatment of various cancers, including metastatic testicular tumors, metastatic ovarian tumors, lung cancer, malignant lymphoma, and chronic myelogenous leukemia. Its mechanism of action involves metabolic activation to form highly reactive intermediates that cross-link DNA strands by covalent bonding. This disrupts DNA replication and transcription in cancer cells, leading to cell death (apoptosis). The drug may also generate reactive oxygen species during redox cycling that contribute to its cytotoxic effects. Carboquone was synthesized and developed by Arakawa et al. at Sankyo in 1970 and has been used primarily in Japan since the 1970s[1][2][4][5][6]. Carboquone is structurally related to mitomycin and other aziridine derivatives. It has demonstrated significant antitumor activity but is associated with considerable side effects such as hematological toxicity (leukopenia, thrombocytopenia) and gastrointestinal disturbances[5][6]. Combination regimens with cisplatin or prednisone have been explored to enhance efficacy or reduce toxicity.

Brand names

CarbotinEsquinon

Other names

carboquonecarbazilquinonecarboquonacarboquonumcarbazilequinone